Wall Street analyst estimates for Universal Health Services, Inc. (UHS): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Universal Health Services, Inc. (UHS), operating through its various divisions, is a healthcare entity that both owns and manages a network of acute care hospitals, along with outpatient and specialized behavioral health treatment centers. Its business operations are strategically bifurcated into two main segments: Acute Care Hospital Services and Behavioral Health Care Services.
Consensus price target
$193.00 (+12 % vs price $172.18)
between $166.00 and $290.00 · 7 targets published in the last quarter
Closing price, Oct 28
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $18.6B | $18.5B – $18.9B | $22.53 | 11 |
| 2027E | $19.5B | $19.2B – $20.0B | $23.96 | 12 |
| 2028E | $20.4B | $19.3B – $21.1B | $26.20 | 9 |
Figures in USD · consensus as of October 28, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 17 |
| Hold | 25 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 44 |
| Avg rating (−2 sell to +2 buy) | 0.34 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-24 | $5.76 | ||
| 2026-10-27 | $5.22 | $5.19 | +0.6% |
| 2026-07-27 | $5.98 | $5.94 | +0.7% |
| 2026-04-27 | $5.62 | $5.41 | +3.9% |
| 2026-02-25 | $5.88 | $5.92 | -0.7% |
| 2025-10-27 | $5.69 | $4.66 | +22.1% |
| 2025-07-28 | $5.35 | $4.92 | +8.7% |
| 2025-04-28 | $4.84 | $4.35 | +11.3% |
Valuation Ratios
| P/E Ratio | 7.22 |
| Price / Book | 1.33 |
| EV / EBITDA | 5.37 |
| Dividend Yield | 0.46% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.77B | $10.41B | $10.77B | $11.38B | $11.56B | $12.64B | $13.40B | $14.28B | $15.83B | $17.36B |
| Cost of Revenue | $1.03B | $1.11B | $1.17B | $1.25B | $1.29B | $1.43B | $1.47B | $1.53B | $1.59B | $1.66B |
| Gross Profit | $8.73B | $9.30B | $9.60B | $10.13B | $10.27B | $11.21B | $11.93B | $12.75B | $14.24B | $15.71B |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $4.68B | $5.08B | $5.36B | $5.70B | $5.73B | $6.28B | $6.89B | $7.25B | $7.67B | $8.23B |
| Operating Expenses | $7.45B | $8.02B | $8.43B | $8.91B | $8.91B | $9.85B | $10.92B | $11.57B | $12.56B | $13.71B |
| Operating Income | $1.28B | $1.28B | $1.18B | $1.22B | $1.36B | $1.36B | $1.00B | $1.18B | $1.68B | $1.99B |
| EBITDA | $1.68B | $1.72B | $1.63B | $1.72B | $1.87B | $1.91B | $1.58B | $1.72B | $2.27B | $2.74B |
| Interest Expense | $116.7M | $142.8M | $155.0M | $162.7M | $109.1M | $85.3M | $127.3M | $207.2M | $187.5M | $157.3M |
| Pre-tax Income | $1.16B | $1.14B | $1.03B | $1.07B | $1.25B | $1.29B | $866.3M | $940.4M | $1.50B | $1.97B |
| Income Tax | $409.2M | $363.7M | $236.6M | $238.8M | $299.3M | $305.7M | $209.3M | $221.1M | $334.8M | $461.0M |
| Net Income | $702.4M | $752.3M | $779.7M | $814.9M | $944.0M | $991.6M | $675.6M | $717.8M | $1.14B | $1.49B |
| EPS | $7.22 | $7.86 | $8.36 | $9.16 | $11.06 | $11.99 | $9.23 | $10.35 | $17.16 | $23.42 |
| EPS (Diluted) | $7.14 | $7.81 | $8.32 | $9.13 | $10.99 | $11.82 | $9.14 | $10.23 | $16.82 | $23.10 |
| Shares Outstanding (Diluted) | 98.4 M | 96.3 M | 93.8 M | 89.0 M | 85.6 M | 83.7 M | 73.8 M | 70.1 M | 67.9 M | 64.5 M |
Price
| Price | $172.18 (closing price, October 28, 2026) |
| Market Cap | $8.9B |
| Exchange | NYSE |
| Country | US |
Related companies: ACHC · HCA · THC · FMS · CHE
Explore sector: Healthcare · Medical - Care Facilities
More sections of UHS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks